uniQure's Huntington's Gene Therapy Shows 80% Slowing of Disease Progression at 36 Months
QURE sits 35% above its 52-week low of $8.73.
Summary
uniQure reported new data from its Phase I/II studies of ifezuntirgene inilparvovec (AMT-130) in Huntington's disease. The updated 36-month analysis, now including 15 high-dose patients, showed 80% slowing of disease progression on cUHDRS (nominal p=0.005) and 67% on TFC (p=0.011). At 48 months, the effect was 44% on cUHDRS (p=0.144) and 61% on TFC (p=0.008), with a post-hoc analysis using prior controls showing 53.5% and 68.3% slowing respectively. These results strengthen the BLA submitted earlier this month, though the 48-month cUHDRS miss on significance may raise questions. The company will host a conference call at 8:30 a.m. ET today to discuss the data.
Updates
· SEC 8-K — The 8-K attaches the presentation and press release with the updated 36-month and 48-month AMT-130 data.
At the time of this announcement, QURE was trading at $11.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $8.73 to $71.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.